Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model

S E Campbell, D Bennett, L Nasir, E A Gault, D J Argyle

Research output: Contribution to journalArticlepeer-review

Abstract

The potential for undesirable systemic effects related to constitutive expression of certain therapeutic transgenes may be limited through the development of transcriptionally targeted disease- and cell-type-specific vectors. The objective of this study was to analyse the canine matrix metalloproteinase-9 (MMP-9) promoter and deletion constructs for its ability to drive expression in response to pro-inflammatory cytokines (interleukin-1beta and tumour necrosis factor-alpha).
Original languageEnglish
Pages (from-to)735-43
Number of pages9
JournalRheumatology
Volume44
Issue number6
DOIs
Publication statusPublished - Jun 2005

Keywords

  • Animals
  • Base Sequence
  • Cell Line, Tumor
  • Collagen Type XI
  • Disease Models, Animal
  • Dogs
  • Gene Deletion
  • Genetic Therapy
  • Genetic Vectors
  • High Mobility Group Proteins
  • Interleukin-1
  • Introns
  • Matrix Metalloproteinase 9
  • Mice
  • Mutation
  • NF-kappa B
  • Osteoarthritis
  • Promoter Regions, Genetic
  • SOX9 Transcription Factor
  • Transcription Factors
  • Transcription, Genetic
  • Tumor Necrosis Factor-alpha

Fingerprint

Dive into the research topics of 'Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model'. Together they form a unique fingerprint.

Cite this